ArticleFrontiers in medicine2026
Kaposiform lymphangiomatosis-the effects of long-term treatment with sirolimus: case series study and review of the literature.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Kaposiform lymphangiomatosis (KLA) is an ultrarare disease characterized by abnormal lymphatic vessel proliferation due to hyperactivation of the Rat sarcoma virus (RAS) signaling pathway, resulting in multifocal lymphatic malformations (LMs) that can potentially involve multiple organ systems. Its distinctive histologic features include the presence of clusters of spindle cells expressing clusters of differentiation 31 (CD31), cluster of differentiation 34 (CD34), podoplanin (D2-40), prospero homeobox protein 1 (PROX1), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), along with abnormal lymphatic vessels. Sirolimus is recommended as a treatment option, particularly for patients without known mutations. This study aimed to examine the long-term therapeutic effects of sirolimus treatment in adult patients with KLA. Materials and methods: Between 2016 and 2024, KLA was diagnosed in three women, aged 21, 35, and 46 years, based on clinical presentation, laboratory findings, and imaging studies, and the diagnosis was confirmed by histological examination. The administration of sirolimus was initiated in all three cases at a therapeutic dose. Results: Treatment resulted in clinical improvement, partial regression, and subsequent stabilization of fluid volume in the pleural cavities, along with reductions in the severity of anemia and hypofibrinogenemia, accompanied by a decrease in D-dimer concentration. Sirolimus proved to be a relatively effective treatment in this group of KLA patients; however, some beneficial effects were not sustained after 5 years of follow-up. The most common side effects included mucositis and lipid disorders. We also reviewed the literature regarding sirolimus treatment in KLA patients. Conclusion: Overall, sirolimus in KLA patients is an effective treatment option with acceptable toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.